HPV Newsletters

Insight HPV for OB/GYNs - Summer 2005

Issue Date: August 5, 2005    Expires: August 5, 2008

In this issue of Insight HPV, we review several case studies that illustrate the appropriate application of HPV DNA testing, new screening recommendations, and the identification of vaginal lesions.

This program is designated for a maximum of 0.5 credits in category 1 of the Physician's Recognition Award of the American Medical Association.

Release Date: August 5, 2005
Expiration Date: August 5, 2008

Learning Objectives

After reading this publication, the participant should be able to:

• Discuss with patients the appropriate use of the human papillomavirus (HPV) DNA test as a diagnostic tool
• Identify and assess vaginal lesions
• Evaluate current guidelines and recommendations about Papanicolaou (Pap) screening, particularly in regards to frequency of screening

Faculty

J.Thomas Cox, MD

Director of the Gynecology and Colposcopy Clinic University of California, Santa Barbara
Past Executive Medical Director National HPV and Cervical Cancer Prevention Resource Center, American Social Health Association Raleigh-Durham, NC
Disclosures: Dr. Cox participates in speakers' bureaus for Digene and 3M Pharmaceuticals. He also serves as a consultant to Digene and 3M Pharmaceuticals. Dr. Cox serves on the data and safety monitoring board for Merck & Co.'s worldwide quadravalent HPV vaccine.

Henry Buck, MD

Head, Gynecology
Watkins Memorial Health Center
University of Kansas
Lawrence, KS
Disclosures: Dr. Buck has received grant/research support from Merck Research Laboratories and served as a consultant to 3M Pharmaceuticals and Merck & Co. Dr. Buck has participated in speakers' bureaus for 3M Pharmaceuticals, Digene, and TriPath, and has served on an advisory board for Merck & Co.

Stanley Gall, MD

Donald E. Baxter Professor and Chairman Emeritus Department of Obstetrics and Gynecology University of Louisville Health Sciences Center Louisville, KY
Disclosures: Dr. Gall has received grant/research support from and served as a consultant to Merck & Co., GlaxoSmithKline, and 3M Pharmaceuticals. Dr. Gall has participated in speakers' bureaus for Merck & Co., 3M Pharmaceuticals and Pfizer and has served on an advisory board for Merck & Co. and GlaxoSmithKline.

About this CME Activity

Please read the publication, reflection on its content, complete the CME Self-Assessment and CME Evaluation and return them to the address indicated. Upon receipt, your certificate of completion will be sent to you with the correct answers to the CME Self-Assessment. The estimated time a leaner will need to complete this self study activity is .5 hours.